This underscores the importance of ongoing clinical support rather than relying on a one-time prescription. For those who discontinue treatment, studies have shown that many patients regain at least some of the weight they lost
GLP-1R agonists exhibit protective and regulatory effects on blood glucose levels but have been linked to the inhibition of tumor cell proliferation in most cancer cases, as seen in vitro and summarized in Table 1 [51, 73]
NAD+ levels rise reliably with NAD precursor supplementation in placebo-controlled trials
Reduced tonic inhibition in the dentate gyrus contributes to chronic stress-induced impairments in learning and memory
The "gradual decline" group (approximately 40-50% of users) represents modal experience where benefits slowly regress toward pre-treatment baseline over 4-8 months, typically affecting users who completed shorter treatment courses (2-4 months), used lower concentrations or inconsistent application, possessed moderate to severe baseline skin damage requiring ongoing support, maintained adequate but not optimal complementary skincare, experienced significant lifestyle stressors affecting skin health including poor sleep or high stress, and faced genetic or age-related collagen production limitations
Barton W, Penney NC, Cronin O, Garcia-Perez I, Molloy MG, Holmes E, Shanahan F, Cotter PD, Osullivan O